BMO Capital Cuts Price Target on Jazz Pharmaceuticals (JAZZ) to $192
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St opens lower as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- US dollar briefly falls vs yen after GDP data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Jazz Pharmaceuticals (JAZZ): Cutting PT ~30% - Mizuho
November 9, 2016 6:23 AM ESTMizuho Securities analyst, Irina Koffler, reiterated her Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) but cut her price target to $127.00 from $185.00.
The estimate and PT cuts reflect a 3Q:16 miss and disclosure of a potentially disappointing Xyrem life-cycle extension product. The analyst... More
After-Hours Movers 11/08: (SAEX) (ARTX) (GMED) Higher; (TRIP) (MPSX) (JAZZ) Lower (more...)
November 8, 2016 6:05 PM ESTToday's After-Hours Movers
SAExploration Holdings, Inc. (NASDAQ: SAEX) 21.8% HIGHER; announced a new project award for seismic data acquisition services valued at approximately $35 million.
TripAdvisor (NASDAQ: TRIP) 13.3% LOWER; reported Q3 EPS of $0.53, in-line with the analyst estimate of $0.53. Revenue for the quarter came in at $421 million versus the consensus estimate of $436.31 million.
Arotech Corp. (NASDAQ:... More
Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c; Guides In-Line
November 8, 2016 4:09 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.57, $0.04 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $374 million versus the consensus estimate of $389.23 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2016 EPS of $9.90-$10.30, versus the consensus of $10.06.... More
Trading Radar for 11/8: D. R. Horton (DHI), Valeant Pharma (VRX), CVS Health (CVS), Valvoline (VVV) Report
November 7, 2016 2:35 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
AerCap Holdings (NYSE: AER) - consensus EPS $1.44
Albany Molecular Research (Nasdaq: AMRI) - consensus EPS $0.17
Alliance One Int'l (NYSE: AOI) - no Street consensus
Apollo Investment Corp. (Nasdaq: AINV) - consensus EPS $0.17
Astronics Corp (Nasdaq: ATRO) - consensus EPS $0.57
CECO Environmental (Nasdaq:... More
